News & Events

Dual Approach Shows Promise in Advanced KRAS G12C-Mutated Lung Cancer

Dual Approach Shows Promise in Advanced KRAS G12C-Mutated Lung Cancer

Genomic pathogenic alterations in the SWI/SNF complex compromise the outcomes of immunotherapy in Chinese patients with KRAS-mutant NSCLC by downregulating STING expression

Genomic pathogenic alterations in the SWI/SNF complex compromise the outcomes of immunotherapy in Chinese patients with KRAS-mutant NSCLC by downregulating STING expression

A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer

A PP2A molecular glue overcomes RAS/MAPK inhibitor resistance in KRAS-mutant non–small cell lung cancer

Jacobio's KRAS G12C and SHP2 Combination Therapy Published in The Lancet Respiratory Medicine

Jacobio's KRAS G12C and SHP2 Combination Therapy Published in The Lancet Respiratory Medicine

Clinical Trial: KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene...

Clinical Trial: KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene...

U.S. Clinical Trial: Merck Sharp & Dohme LLC Listed a New Clinical Trial to Study Pembrolizumab Plus MK-1084 in Participants with Non-Small Cell Lung Cancer...

U.S. Clinical Trial: Merck Sharp & Dohme LLC Listed a New Clinical Trial to Study Pembrolizumab Plus MK-1084 in Participants with Non-Small Cell Lung Cancer...

KRAS mutations and lung cancer: Treatment and outlook

KRAS mutations and lung cancer: Treatment and outlook

KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects

KRAS G12C-associated immunotherapy benefit in NSCLC is substantially mediated by tobacco-induced tumor mutation burden, not allele-specific effects